Hide filtersShow filters × Close Bryan Garnier & Co advises GeNeuro on its Euronext IPO, raising €33 million, acting as Global Coordinator & Joint Bookrunner Equity Issue SparebankenVest AS Bryan Garnier & Co advises DBV Technologies on its follow-on offering, raising $281.5m in July 2015, acting as financial advisor Bryan, Garnier & Co announces the successful €13.2m Euronext IPO of Amoéba Bryan, Garnier & Co announces the successful $100m Nasdaq IPO of Celyad. Bryan, Garnier & Co announces that the total proceeds of Galapagos IPO on Nasdaq, the largest Nasdaq IPO of a European biotech, have been raised to $317m following the full exercise of over-allotment option. Bryan, Garnier & Co announces the successful follow-on offering of £20m for Advanced Oncotherapy plc Bryan, Garnier & Co announces the successful IPO of Bone Therapeutics. Bryan, Garnier & Co announces the IPO of Quantum Pharma on London AIM Bryan, Garnier & Co acts as Global Coordinator and Bookrunner of a Follow-on Offering of €30m for Erytech Pharma Bryan, Garnier & Co acts as Joint Lead Manager and Joint Bookrunner of DBV $133m IPO on NASDAQ. Bryan, Garnier & Co advises Voltalia on its transfert to Euronext and €100m Capital Increase
